Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma

详细信息    查看全文

• 作者：Shingo Kanemura^a ; ¹ ; Kozo Kuribayashi^a ; ¹ ; ^{kuririn@hyo-med.ac.jp} ; Norihiko Funaguchi^b ; Eisuke Shibata^a ; Koji Mikami^a ; Hiroshi Doi^c ; Kazuhiro Kitajima^d ; Seiki Hasegawa^e ; Takashi Nakano^a
• 关键词：FDG-PET ; 18F-fluorodeoxyglucose positron emission tomography ; MPM ; Malignant Pleural Mesothelioma ; mRECIST ; Modified Response Evaluation Criteria in Solid Tumors ; Metabolic Response
• 刊名：European Journal of Radiology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：86
• 期：Complete
• 页码：92-98
• 全文大小：1162 K
• 卷排序：86

文摘

18F-FDG-PET/CT and mRESIST were used for tumour responsiveness evaluation in MPM. 29% of mRESIST stable disease (SD) patients were metabolic non-responders. Disease control rate was 93.9% and metabolic response rate was 71.9%. Progressive metabolic disease patients had lower time to progression. MRESIST stable disease (SD) patients should be further screened by 18F-FDG-PET/CT.